SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as traders discuss a recent market dip, with some attributing it to external factors like tariff concerns and others pointing to market manipulation and leveraged positions being liquidated. The community is debating whether this is a temporary setback or the start of a larger correction, with opinions split between those expecting a quick recovery and those bracing for further declines. Despite the volatility, the long-term outlook for Bitcoin and its role as a store of value remain central talking points.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is experiencing a significant selloff, driven by concerns around potential tariffs and broader market anxieties, leading to a massive liquidation event. The community is debating the impact of these factors and whether this is a buying opportunity or the start of a deeper correction. Some are calling for prominent figures like Tom Lee to address the situation, while others are focusing on potential buying opportunities if the price continues to decline.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as community members discuss its potential breakout and recent price action, with some speculating about new highs and comparing it to Bitcoin. The conversation highlights ZEC's potential leadership in the altcoin market and its resilience during market dips, while also questioning whether it's a pump based on fundamentals or just technicals. Some traders are noting its dominance and growing volume relative to Bitcoin.

Clown Pepe, also known as Honk, its original name pepoclown, is a depiction of Pepe the Frog wearing a rainbow wig and red clown nose.  $HONK, the meme coin with 0 taxes, draws its inspiration from Clown Pepe, also known as Honk Honk or Honkler. This whimsical character, originally named pepoclown, depicts Pepe the Frog donning a rainbow wig and a red clown nose. Honkler is often associated with corny or cringeworthy jokes and the emojis, symbolizing the phrase "Clown World." Embracing the chaotic and absurd nature of meme culture, $HONK aims to bring humor, memes and vibes to the space.

Pepoclown

HONK is trending as a potential successor to PEPE, with community members highlighting its roots in 4chan culture and its association with the "clown world" meme. Some community members draw attention to the possibility of it being the next 4Chan meme to blow up. Bullish sentiment seems to be driven by the idea of it as an undervalued opportunity within the Ethereum memecoin ecosystem.

GSR III Acquisition Corp engages in the merger, share exchange, asset acquisition, share purchase or reorganization with one or more businesses. The company was founded on May 10, 2023 and is headquartered in Austin, Texas.

Terra Innovatum Global N.V.

Terra Innovatum Global N.V. Ordinary shares

Terra Innovatum Global N.V. (NKLR) is trending following its ticker change, sparking discussions about its valuation relative to other nuclear plays like $OKLO and $SMR. The community is also watching for brokerages to fully update the ticker, with some users reporting delays in trading the new symbol or converting existing shares. Some see potential for a significant run, citing the low float and growing interest in the nuclear energy sector.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic ($LUNC) is trending as the community discusses its price action and potential for future growth. Despite some community members expressing frustration with recent price decreases, others are buying the dip and emphasizing long-term holding strategies. There's also discussion around community projects and potential catalysts for a rebound.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is experiencing significant volatility, sparking intense debate within the community. A recent flash crash, possibly triggered by broader market concerns or tariff announcements, led to widespread liquidations and trading halts, with some users alleging market manipulation. Despite the turmoil, dip buyers emerged, and the community is closely watching for a potential rebound, while remaining wary of further dumps.

ProShares Trust - ProShares Short Bitcoin ETF

ProShares Short Bitcoin Strategy ETF

BITI is trending as traders discuss potential downside for Bitcoin, with some noting technical indicators suggesting a possible pullback. Community members are debating optimal entry points for BITI, inverse ETF on Bitcoin, while considering factors like election outcomes and broader market trends. Sentiment ranges from those expecting a near-term crypto crash to others anticipating higher Bitcoin prices, creating active discussion around hedging strategies.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as traders discuss a significant market dip and its potential impact, with many users sharing experiences of liquidations and missed buying opportunities. Community members are debating whether the dip was caused by market manipulation, a broader economic downturn, or a combination of factors, while others remain optimistic about long-term prospects and potential ETF developments. The conversation also includes commentary on the role of influential figures and exchanges in the recent price action.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending due to market reactions to escalating US-China trade war tensions and concerns about potential economic impacts, particularly regarding rare earth minerals and retaliatory tariffs. Community discussions revolve around the dollar's decline, potential impacts on tech companies, and the effectiveness of current trade policies. Investors are weighing the broader implications of these developments on the overall stock market and global economy.

statis crypto Watchlist

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal

Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.

Merus&nbsp;NV’s stock climbed to a record high on Monday after Genmab said it would acquire the company in an $8 billion all-cash transaction, despite a broad wave of analyst downgrades.<a href="https://stocktwits.com/symbol/MRUS">Shares of Merus</a> jumped 36% to close at $93.70 on Monday, before edging up 0.1%, in after-hours trading.Needham analyst Ami Fadia downgraded Merus to ‘Hold’ from ‘Buy’ without a price target after the company entered into the agreement. Citi downgraded the stock to ‘Neutral’ from ‘Buy’ and cut its price target to $97 from $101, saying the possibility of a competing bid is very low.Wells Fargo analyst Eva Fortea Verdejo lowered her rating to ‘Equal Weight’ from ‘Overweight’ and raised the price target to $97 from $95. Canaccord downgraded Merus to ‘Hold’ from ‘Buy’ with a price target of $97, while William Blair cut its rating to ‘Market Perform’ from ‘Outperform’.Truist moved Merus to ‘Hold’ from ‘Buy’ and raised the price target to $97 from $88, saying the deal terms are “favorable, all things considered.”LifeSci Capital analyst Charles Zhu downgraded Merus to ‘Market Perform’ from ‘Outperform’ with a price target of $97. Guggenheim analyst Michael Schmidt downgraded the stock to ‘Neutral’ from ‘Buy’ and cut the target to $97 from $109.H.C. Wainwright downgraded Merus to ‘Neutral’ from ‘Buy’ and reduced its price target to $97 from $135, saying Merus’ full value is priced into the deal.The transaction, unanimously approved by both companies’ boards, gives Genmab full ownership of petosemtamab, Merus’ late-stage antibody therapy for head and neck cancer, which has received two Breakthrough Therapy Designations from the U.S. Food and Drug Administration.On Stocktwits, retail sentiment for Merus was ‘extremely bullish’ amid a 3,800% surge in 24-hour message volume.Some users congratulated Merus shareholders on the buyout, saying the acquisition marked a rewarding moment for long-term investors who held through difficult periods.<stembedurl>https://stocktwits.com/BiotechBonesaw/message/630422083</stembedurl><stembedurl>https://stocktwits.com/Following_the_trend/message/630325826</stembedurl>Another user noted that the deal underscored the potential for other biotech firms to be acquired at higher valuations, citing that Merus was acquired by Genmab for $8 billion, despite its focus on the relatively smaller head and neck cancer market.<stembedurl>https://stocktwits.com/Power2k/message/630394868</stembedurl><a href="https://stocktwits.com/symbol/MRUS">Merus’ stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Merus logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal

The $8 billion all-cash deal gives Genmab full ownership of Merus’ late-stage antibody therapy petosemtamab, which has received two FDA Breakthrough Therapy Designations for head and neck cancer.

Equity

Retail chatter around Merus spiked late on Sunday after a report said Denmark’s Genmab is reportedly in advanced talks to acquire the Dutch biotech, which is developing a potential treatment for head and neck cancer.<a href="https://stocktwits.com/symbol/MRUS">Merus’ U.S.-listed stock</a> closed at $68.89 on Friday, up 1.2%, and surged over 19% to $82.03 in overnight trading.Merus has reportedly received multiple takeover offers from large pharmaceutical companies in recent weeks and could announce a deal within days, although there is no certainty that the talks will result in a transaction, Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-28/genmab-is-said-in-talks-to-buy-cancer-drugmaker-merus?srnd=homepage-americas&amp;sref=8QBk7toa">reported</a>, citing people familiar with the matter.If finalized, the deal would be Genmab’s largest acquisition to date, Bloomberg reported. Genmab has a market capitalization of about 118 billion kroner ($18.5 billion), while Merus is valued at around $5.2 billion on the Nasdaq.Merus’ shares have risen sharply since May, when the company said its experimental drug petosemtamab was more effective than the current standard of care in shrinking tumors in head-and-neck cancer patients when combined with Keytruda. Bloomberg Intelligence has forecast that the drug could become a blockbuster therapy and exceed $1 billion in sales by 2030.Merus is also testing petosemtamab in advanced colon cancer, a larger and more lucrative potential market. Its smaller rival, Bicara Therapeutics, is developing a treatment for the same condition but remains further behind in development.On Stocktwits, retail sentiment for Merus was ‘bullish’ amid ‘high’ message volume, placing the stock among the top ten trending equities on the platform. Meanwhile, Genmab drew ‘extremely bearish’ sentiment amid ‘high’ message volume.One user congratulated the company on the reported development, while another user asked about the potential buyout price, reflecting curiosity about the rumored deal’s details.<stembedurl>https://stocktwits.com/CrispDry/message/630278149</stembedurl><stembedurl>https://stocktwits.com/Fugazi_/message/630280727</stembedurl>Merus’ U.S.-listed stock has risen 63.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race

Merus’ cancer drug petosemtamab, developed for head and neck tumors, has shown stronger results than the current standard of care and is projected to top $1 billion in annual sales by 2030.

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

Merus (MRUS) delivered earnings and revenue surprises of -90.60% and -15.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of +39.81% and +7.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success

Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.

Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the company announcing positive data from one of its ongoing drug trials.Oncology company Merus on Thursday <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.merus.nl/news-releases/news-release-details/merus-petosemtamab-pembrolizumab-interim-data-demonstrates">said</a> that the combination of bispecific antibody Petosemtamab with Pembrolizumab demonstrated robust efficacy and durability in its ongoing phase 2 trial as of Feb. 27.Merus CEO Bill Lundberg said the data from the trial demonstrates that Petosemtamab in combination with Pembrolizumab can become “a new standard of care" in head and neck cancer and is “significantly better” than treatment with just Pembrolizumab.The company said that as of Feb. 27, 45 patients had been treated in the phase 2 trial, and the combination was generally well tolerated.The CEO also expressed optimism about sharing data from one or both of its late-stage combination trials in 2026.BofA on Friday hiked the price target on Merus to $92 from $70 while keeping a ‘Buy’ rating on the shares. The firm noted that the recently announced data set the combination as "the best-in-class treatment option for this patient population."The analyst’s new price target implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.BMO Capital also hiked the price target on Merus to $110 from $96 on Friday while keeping an ‘Outperform’ rating on the shares. BMO said it sees a 90% probability of the combination's approval for treating head and neck cancer.On Stocktwits, retail sentiment around Merus jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_23_at_10_48_55_AM_png_3d759215e6.webp" alt="MRUS's Sentiment Meter and Message Volume as of 10:50 a.m. ET on May 23, 2025 | Source: Stocktwits" width="626" height="63"><figcaption>MRUS's Sentiment Meter and Message Volume as of 10:50 a.m. ET on May 23, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/MRUS">MRUS stock</a> is up by about 30% this year and 25% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jp-morgan-bank-of-america-citigroup-wells-fargo-reportedly-explore-joint-stablecoin/ch0QZ5vRbqs">JPMorgan, Bank of America, Citigroup, Wells Fargo Reportedly Explore Joint Stablecoin</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled

BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.

Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline

Sarepta, other biotech stocks tumble as FDA appoints new CBER director

Investing.com -- Shares of several biotech companies experienced significant declines in Tuesday’s trading session following the announcement of Dr. Vinay Prasad as the new director of the Center for Biologics Evaluation and Research (CBER) at the FDA. Modernal stock fell 12%,  Sarepta  Therapeutics (NASDAQ:SRPT) shares dropped 25%, Capricor Therapeutics (NASDAQ:CAPR) plummeted 24%, and Arcellx declined by 16%.

Lightning Round: Take some Sterling Infrastructure off the table, let the rest run, says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stock including: Allison Transmission, Nano Nuclear Energy, Sterling Infrastructure, and Merus...

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

MRUS
Merus N.V

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRUS News

MRUSMerus N.V